A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by IntratumoralInjection as Monotherapy and in Combination with Pembrolizumab or by SubcutaneousInjection in Combination with Pembrolizumab for Patients with Advanced/MetastaticSolid Tumors or Lymphomas
Study of Drug (MK-2118) in Patients with Solid Tumors or Lymphomas
Sponsor: Merck
Enrolling: Male and Female Patients
IRB Number: AAAR4398
U.S. Govt. ID: NCT03249792
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to: test the safety of the study drug and see how your body handles it, find the highest dose of the study drug that can be given alone or in combination with embrolizumab (MK-3475) with the least risk of serious side effects. The study drug is called MK-2118. Solid tumor or lymphoma cancers include: bladder cancer, breast cancer, esophageal cancer, kidney cancer, adrenal cancer, lung cancer, sarcomas, gynecologic cancers, lymphoma, pancreatic cancer, stomach cancer, colon and rectal cancer, head/neck/oral cancers, liver cancer, and prostate cancer.
Investigator
Matthew Ingham, MD
Do You Qualify?
Have you been diagnosed with a solid tumor or lymphoma cancer? (Types of cancer listed in description.) Yes No
Do you have stage 3 or 4 disease that cannot be removed by surgery? Yes No
Are you able to walk, care for yourself, and do light physical activities like light housework or office work? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162